ABBV-400(Telisotuzumab Adizutecan)是艾伯维筛选了超过400种连接子-载荷后得到cMET靶向ADC,,也是艾伯维开发的第二款cMET靶向ADC,抗体部分仍然为telisotuzumab与Teliso-V保持一致,载荷为TOPO1i。 ABBV-400推测结构 刚刚结束的2024年ESMO会议上,艾伯维公布了NCT...
引言 近日,美国杜克癌症研究所的Strickler教授在接受采访时,介绍了一种名为Telisotuzumab Adizutecan(ABBV-400)的新型抗体偶联药物(ADC),该药靶向c-Met蛋白,已被证实对结直肠癌患者有治疗效果,且副作用可被耐受。研究数据显示,在c-Met...
一项1期试验(NCT05029882)的数据显示,靶向c-Met的新型ADC药物ABBV-400在BRAF野生型、微卫星稳定型(MSS)/错配修复良好型(pMMR)晚期结直肠癌(CRC)患者中显示出初步的抗肿瘤活性,且患者耐受性良好。港安健康国际医疗介绍,ABBV-400将c-Met靶向抗体telisotuzumab与拓扑异构酶1抑制剂有效载荷相结合。c-Met的过表达在...
3030#Background:ABBV-400 is an antibody drug conjugate (ADC) consisting of a c-Met targeting antibody conjugated to a potent inhibitor of topoisomerase 1 (Top1) payload. ABBV-400 has shown encouraging activity and demonstrated tolerability of dosages up to 3.0 mg/kg Q3W as monotherapy in ...
3030#Background:ABBV-400 is an antibody drug conjugate (ADC) consisting of a c-Met targeting antibody conjugated to a potent inhibitor of topoisomerase 1 (Top1) payload. ABBV-400 has shown encouraging activity and demonstrated tolerability of dosages up to 3.0 mg/kg Q3W as monotherapy in pati...
ADC Related AhR Autophagy Dynamin FLAP Interleukin Related LpxC LRRK2 NLR Others PROTAC STING TLR Vitamin D Related PI3K/Akt/mTOR PI3K/Akt/mTOR AKT AMPK ATM/ATR DNA PK GSK3 MELK mTOR PDK PI3K PI4K PTEN RSK Protease/Metabolic Enzyme Protease/Metabolic Enzyme 11β HSD ACC ALDH Aldose ...
一项1期试验(NCT05029882)的数据显示,靶向c-Met的新型ADC药物ABBV-400在BRAF野生型、微卫星稳定型(MSS)/错配修复良好型(pMMR)晚期结直肠癌(CRC)患者中显示出初步的抗肿瘤活性,且患者耐受性良好。港安健康国际医疗介绍,ABBV-400将c-Met靶向抗体telisotuzumab与拓扑异构酶1抑制剂有效载荷相结合。c-Met的过表达在...
英文名ABBV-2222 中文别名 英文别名ABBV 2222; ABBV2222; GLPG2222; GLPG-2222; GLPG 2222; SMILES 化学名称 分子式C28H21F4NO7分子量559.47 纯度98%配送惯例下常温包邮 产品描述ABBV-2222, also known as GLPG2222, is a CFTR corrector being studied for the treatment of cystic fibrosis (CF). ...